DOCSLIB.ORG

A Acetylcholine Anticholinergic Drugs, 49 Cholinergic Wake-Promoting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Acetylcholine Anticholinergic Drugs, 49 Cholinergic Wake-Promoting Index A C Acetylcholine Cataplexy anticholinergic drugs, 49 GHB, 37 cholinergic wake-promoting system, 48 narcolepsy type 1, 215 cholinesterase inhibitors, 48–49 narcolepsy type 2, 215 milameline, 49 sleep-promoting orexinergic inhibitors, 46 nicotine, 49 SXB, 238–240 receptors, 48 tricyclic antidepressants, 253 sleep-promoting cholinergic Cell replacement therapy, 253 inhibitors, 49 Central sleep apnea (CSA) syndrome, 76 Adenosine Cheyne–Stokes breathing (CSB), 76 adenosine-mediated sleep-promoting Cholinesterase inhibitors system, 41 donepezil, 49 receptors, 42 physostigmine, 48 sleep-promoting adenosine receptor Chronic insomnia agonists, 42 dose discrimination, lack of, 168 wake-promoting adenosine receptor psychiatric comorbidities, 169 antagonists, 42 short-term efficacy and long-term safety, Amantadine, 77 167–168 Armodafinil sleep induction and maintenance, 168–169 chemical structure, 212 Chronic obstructive sleep apnea multiple sclerosis, 222 (OSA), 178–179 narcolepsy, 218 Chronic primary insomnia obstructive sleep apnea, 219–221 adverse effects, 165, 167 pharmacokinetics, 214 comorbid psychiatric disorders, 164 R enantiomer, 213 double-blind trial, 164 safety, 224–225 efficacy, 165 shift work disorder, 223 long-term trial, 165 open-label extension phase, 165 post hoc analysis, 165–166 B psychomotor performance, 164–165 Benzodiazepine Withdrawal Symptom rebound insomnia, 164 Questionnaire (BWSQ), 183 WASO, 164–165 © Springer International Publishing Switzerland 2015 289 A. Guglietta (ed.), Drug Treatment of Sleep Disorders, Milestones in Drug Therapy, DOI 10.1007/978-3-319-11514-6 290 Index Chronic primary insomnia (cont.) re-profiling/extension, marketed drug, zolpidem, 166 282–283 Chronobiotics, 78 subsets of patients, 283–284 Circadian rhythm sleep–wake disorder DST. See Digit span test (DST) (CRSWD), 73, 78 Dual orexin receptor antagonists (DORAs) Clinical Global Impression of Change (CGI) advantages, 199, 201–202 scores, 216–217, 241 almorexant, 198–199 Clonazepam, 81 SB-649868, 199–200 Comorbid insomnia suvorexant, 199–201 cancer pain, 180–181 clinical trials, 170–173 GAD, 176–177 E MDD, 174–176 Eszopiclone multiple sclerosis, 180 administration dosage, 181 OSA, 178–179 clinical efficacy and safety Parkinson’s disease, 179–180 chronic insomnia, 167–169 perimenopausal and postmenopausal chronic primary insomnia (see Chronic women, 170, 174 primary insomnia) PTSD, 177 clinical trials, 161–163 pulmonary disease, 178–179 improvements, 169–170 rheumatoid arthritis, 179 transient insomnia, 161, 164 comorbid insomnia cancer pain, 180–181 D clinical trials, 170–173 Digit span test (DST), 134 GAD, 176–177 Dopamine MDD, 174–176 dopaminergic wake-promoting multiple sclerosis, 180 system, 55–56 OSA, 178–179 PLMD, 81 Parkinson’s disease, 179–180 receptors, 56 perimenopausal and postmenopausal RLS, 80–81 women, 170, 174 sleep-promoting dopaminergic inhibitors PTSD, 177 monoamine depletors, 58 pulmonary disease, 178–179 postsynaptic D1 and D2 receptor rheumatoid arthritis, 179 antagonists, 58 drug interaction, 181 presynaptic D2 receptor agonists, 58 hypnotics, 183–184 wake-promoting dopaminergic activators mechanism of action, 160 dopamine release promoters, 57 multicenter trials, 184–185 dopamine reuptake inhibitors, 56–57 pharmacokinetic parameters, 160–161 postsynaptic D1 and D2 dopamine pharmacology, 160 receptor agonists, 57 placebo-controlled trials, 184–185 presynaptic D2 dopamine receptor randomized trials, 184–185 antagonists, 57 tolerability profile DORAs. See Dual orexin receptor antagonists adverse event profile, 182 (DORAs) BWSQ, 183 Dorsomedial hypothalamus (DMH), 32 cognitive/psychomotor function, Doxepin. See Low-dose doxepin 182–183 Drug indications confusion rates, 182 design, 284–285 GABAA receptors, 182 pathophysiology, biochemistry, and memory impairment, 182 pharmacology, 283 treatment duration, 183 Index 291 unpleasant and bitter taste, 182 wake-promoting glutamatergic Excessive daytime sleepiness (EDS). See activators, 47 Modafinil G protein-regulated inward rectifier Exploding head syndrome (EHS), 73, 79–80 (GIRK), 193 G H GABA. See γ-aminobutyric acid (GABA) Histamine GABAA receptor modulators histaminergic wake-promoting system, 43 anaesthetic site, 36 receptors, 43 barbiturate receptor, 36 sleep-promoting histaminergic inhibitors, benzodiazepine receptor, 36 44–45 ethanol site, 37 wake-promoting histaminergic neurosteroids, 37 activators, 44 Galanin Hypersomnolence galaninergic sleep-promoting system, idiopathic hypersomnia, 73, 77 39–40 insufficient sleep syndrome, 73, 78 sleep-promoting galanin receptor Kleine–Levin syndrome, 73, 77 agonists, 40 long sleeper, 73, 78 wake-promoting galanin receptor traumatic brain injury, 221–222 antagonists, 40 type 1 narcolepsy, 72, 77 γ-aminobutyric acid (GABA) type 2 narcolepsy, 73, 77 noradrenergic locus coeruleus, 29, 34, 51 Hypnotic drugs receptors, 34–35 barbiturates, 124–125 sleep-promoting activators benzodiazepines, 124–125 anaesthetic site, 36 infections/cancer, 183–184 baclofen, 37 non-benzodiazepines hypnotics, 125 barbiturate receptor, 36 Hypocretin. See Orexin benzodiazepine receptor, 36 Hypocretin-2/orexin-B (Hcrt-2), 250–251 ethanol site, 37 gaboxadol, 36 GHB, 37 I neurosteroids, 37 ICSD-3. See International Classification of tiagabine, 37 Sleep Disorders (ICSD-3) wake-promoting inhibitors Insomnia disorder benzodiazepine binding site, 38 alkaloids, 276 bicuculline and gabazine, 38 biochemical characterization, 90 flumazenil, 38 chemical molecules, 276 GABAB and GABAC receptors, 38 classification, 72 GABA receptor autoantibodies, 38–39 clinical development phase Generalized anxiety disorder (GAD), 176–177 double-blind studies, 99, 100 Genome-wide association studies (GWAS), 12 efficacy and safety data, 88, 97 γ-hydroxybutyric acid (GHB), 37 parallel group studies, 99 GIRK. See G protein-regulated inward rectifier phase II studies, 98 (GIRK) phase I studies, 97–98 Glutamate phase 0 studies (exploratory IND glutamatergic wake-promoting system, studies), 97 46–47 placebo-controlled studies, 97, 100 receptors, 47 polysomnography method, 99 REMS-suppressing glutamatergic proof-of-concept studies, 98 inhibitors, 48 psychometric method, 99 sleep-promoting glutamatergic randomized studies, 99, 100 inhibitors, 47 clinical features, 75 292 Index Insomnia disorder (cont.) L diagnosis, 75 Lithium carbonate, 77 drug development failure, 86, 87 Lorediplon endogenous molecules replacement chemical structure, 125 approach, 89 GABAA receptor modulation eszopiclone (see Eszopiclone) biological effects, 123 herbal and natural products, 275–276 Cys loop receptors, 122 lorediplon (see Lorediplon) endogenous ligand, 123 low-dose doxepin (see Low-dose doxepin) glycine receptors, 122 molecule-based approach, 89 5-HT3A receptors, 122 nonclinical development phase hypnotic drugs, 124–125 analytical methods development, 91 nicotinic acetylcholine receptors, 122 efficacy and safety data, 88, 90 protein subunits, 122–124 formulation development, 95–96 sedation, 123, 124 manufacturing process, 90–91 pharmacokinetic profile, 133–136 nonclinical safety evaluation (see preclinical and clinical data, 141 Nonclinical safety evaluation) preclinical pharmacology pharmacokinetic and metabolism amnesic effects, 129–130 characterization, 95 GABAA subunits, 126–127 pharmacology development, 96–97 hypnotic and ethanol interactions, 130 orexin (see Orexin) Lorediplon EtOH Liability Index, 130 pharmacology and pharmacokinetic middle-of-the-night awakenings, characterization, 90 131–132 post-approval studies, 88 muscular tone inhibition, 127–129 formulation development, 101 Next-Day Hangover Liability indication, 101 Index, 130 miscellaneous studies, 103 physical dependence, 130, 131 regulatory agency, 101 polygraphic record, 131, 132 safety monitoring (pharmacovigilance), potency, 131 102–103 quality of sleep, 132 prevalence and impact of, 113–114 sedation, 127–128 target-based approach, 88–89 sleep fragmentation, 131 toxicology tests, 90 sleep–wake state, 131, 133 treatment, 75 safety, 139, 141 International Classification of Sleep Disorders vs. zolpidem (ICSD-3) advantages, 141, 142 circadian rhythm sleep–wake disorders, cortical and muscle electrodes, 130 73, 78 DST, 134 degree of standardization, 74–75 next-day residual drug effect, 139 hypersomnolence number of awakenings (W), 137, 139 idiopathic hypersomnia, 73, 77 parameters, 131–133 insufficient sleep syndrome, 73, 78 PSQ, 139, 140 Kleine–Levin syndrome, 73, 77 PVT, 134 long sleeper, 73, 78 SEI, 137, 139 type 1 narcolepsy, 72, 77 sleep onset, 135–137 type 2 narcolepsy, 73, 77 TST, 137, 139 insomnia disorders, 72, 75 VAS, 134 isolated symptoms and normal variants, WASO, 136, 138 74, 81 Lorediplon EtOH Liability Index, 130 parasomnias Low-dose doxepin EHS, 73, 79–80 contraindications, 117 NREM-related parasomnias, 73, 79 dosing, 118 sleep-related hallucinations, 73, 79–80 efficacy, 115–116 sleep-related breathing disorders, 72, 76–77 mechanism of action, 115 SRMD, 74, 80–81 neurotransmitters system Index 293 acetylcholine, 112 N adenosine, 112 Narcolepsy, 12 histamine, 113 amphetamines, 276–277 hypocretin, 113 cell replacement therapy, 253 norepinephrine, 112–113 experimental models serotonin, 112–113 day–night cycle, 252 pharmacokinetics, 115 embryonic day 19 E19, 252 tolerability, 117 end of sleep period (ZT12), 252 Hcrt-2/SAP, 250–251 peptide levels, 252 M prepro-Hcrt gene expression, 252 Maintenance of wakefulness test (MWT), sleep deprivation method, 252 240–241 toxin, 250 Major depressive disorder (MDD), 174–176 wake-active period (ZT0),
Load more

Recommended publications
  • ON ATTRACTION of SLIME MOULD PHYSARUM POLYCEPHALUM to PLANTS with SEDATIVE PROPERTIES 1. Introduction Physarum Polycephalum Belo
    ON ATTRACTION OF SLIME MOULD PHYSARUM POLYCEPHALUM TO PLANTS WITH SEDATIVE PROPERTIES ANDREW ADAMATZKY Abstract. A plasmodium of acellular slime mould Physarum polycephalum is a large single cell with many nuclei. Presented to a configuration of attracting and repelling stimuli a plasmodium optimizes its growth pattern and spans the attractants, while avoiding repellents, with efficient network of protoplasmic tubes. Such behaviour is interpreted as computation and the plasmodium as an amorphous growing biologi- cal computer. Till recently laboratory prototypes of slime mould computing devices (Physarum machines) employed rolled oats and oat powder to represent input data. We explore alternative sources of chemo-attractants, which do not require a sophis- ticated laboratory synthesis. We show that plasmodium of P. polycephalum prefers sedative herbal tablets and dried plants to oat flakes and honey. In laboratory experi- ments we develop a hierarchy of slime-moulds chemo-tactic preferences. We show that Valerian root (Valeriana officinalis) is strongest chemo-attractant of P. polycephalum outperforming not only most common plants with sedative activities but also some herbal tablets. Keywords: Physarum polycephalum, slime mould, valerian, passion flower, hops, ver- vain, gentian, wild lettuce, chemo-attraction 1. Introduction Physarum polycephalum belongs to the species of order Physarales, subclass Myxo- gastromycetidae, class Myxomycetes, division Myxostelida. It is commonly known as a true, acellular or multi-headed slime mould. Plasmodium is a `vegetative' phase, single cell with a myriad of diploid nuclei. The plasmodium looks like an amorphous yellowish mass with networks of protoplasmic tubes. The plasmodium behaves and moves as a giant amoeba. It feeds on bacteria, spores and other microbial creatures and micro- particles (Stephenson & Stempen, 2000).
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • GABAA Transmission Is a Critical Step in the Process of Triggering Homeostatic Increases in Quantal Amplitude
    GABAA transmission is a critical step in the process of triggering homeostatic increases in quantal amplitude Jennifer C. Wilhelm and Peter Wenner* Department of Physiology, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Lynn T. Landmesser, Case Western Reserve University, Cleveland, OH, June 23, 2008 (received for review March 1, 2008) When activity levels are altered over days, a network of cells is models suggests that reducing network activity produces a corre- capable of recognizing this perturbation and triggering several dis- sponding reduction in cellular spiking activity, thereby reducing tinct compensatory changes that should help to recover and maintain intracellular calcium levels in a postsynaptic cell. In this model, the original activity levels homeostatically. One feature commonly which we will refer to as the cell activity model, the postsynaptic cell observed after activity blockade has been a compensatory increase in senses changes in intracellular calcium levels as a measure of altered excitatory quantal amplitude. The sensing machinery that detects activity and triggers compensatory changes in mPSC amplitude. altered activity levels is a central focus of the field currently, but thus However, the studies that have inspired this model not only block far it has been elusive. The vast majority of studies that reduce spiking activity, they also block or reduce neurotransmitter binding network activity also reduce neurotransmission. We address the to its receptor and any associated downstream signaling cascades. possibility that reduced neurotransmission can trigger increases in Thus, it remains possible that neurotransmission is a critical step in quantal amplitude. In this work, we blocked glutamatergic or GABAA the sensing process that triggers changes in quantal amplitude.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Receives Fda Approval for the Treatment of Insomnia
    AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED-RELEASE TABLETS) CIV RECEIVES FDA APPROVAL FOR THE TREATMENT OF INSOMNIA First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population Paris, France, September 6, 2005 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number ® one prescription sleep aid, AMBIEN (zolpidem tartrate) CIV, for the treatment of insomnia. AMBIEN CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to AMBIEN with a new indication for sleep maintenance, in addition to sleep induction. AMBIEN CR is the first and only extended-release prescription sleep medication to help people with insomnia fall asleep fast and maintain sleep with no significant decrease in next day performance. AMBIEN CR, a bi-layered tablet, is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep. “Insomnia is a significant public health problem, affecting millions of Americans. Insomnia impacts daily activities and is associated with increased health care costs,” said James K. Walsh, PhD, Executive Director and Senior Scientist, Sleep Medicine and Research Center at St. Luke's Hospital in St. Louis, Missouri. “Helping patients stay asleep is recognized as being as important as helping them fall asleep,” said Walsh. “Ambien CR has shown evidence of promoting sleep onset and more continuous sleep".
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Bicuculline and Gabazine Are Allosteric Inhibitors of Channel Opening of the GABAA Receptor
    The Journal of Neuroscience, January 15, 1997, 17(2):625–634 Bicuculline and Gabazine Are Allosteric Inhibitors of Channel Opening of the GABAA Receptor Shinya Ueno,1 John Bracamontes,1 Chuck Zorumski,2 David S. Weiss,3 and Joe Henry Steinbach1 Departments of 1Anesthesiology and 2Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, and 3University of Alabama at Birmingham, Neurobiology Research Center and Department of Physiology and Biophysics, Birmingham, Alabama 35294-0021 Anesthetic drugs are known to interact with GABAA receptors, bicuculline only partially blocked responses to pentobarbital. both to potentiate the effects of low concentrations of GABA and These observations indicate that the blockers do not compete to directly gate open the ion channel in the absence of GABA; with alphaxalone or pentobarbital for a single class of sites on the however, the site(s) involved in direct gating by these drugs is not GABAA receptor. Finally, at receptors containing a1b2(Y157S)g2L known. We have studied the ability of alphaxalone (an anesthetic subunits, both bicuculline and gabazine showed weak agonist steroid) and pentobarbital (an anesthetic barbiturate) to directly activity and actually potentiated responses to alphaxalone. These activate recombinant GABAA receptors containing the a1, b2, and observations indicate that the blocking drugs can produce allo- g2L subunits. Steroid gating was not affected when either of two steric changes in GABAA receptors, at least those containing this mutated b2 subunits [b2(Y157S) and b2(Y205S)] are incorporated mutated b2 subunit. We conclude that the sites for binding ste- into the receptors, although these subunits greatly reduce the roids and barbiturates do not overlap with the GABA-binding site.
    [Show full text]
  • Mechanism of Action of Ethylenediamine On
    Stone, T.W., Lui, C. and Addae, J.I. (2010) Effects of ethylenediamine – a putative GABA-releasing agent – on rat hippocampal slices and neocortical activity in vivo. European Journal of Pharmacology, 650 (2-3). pp. 568-578. ISSN 0014-2999. http://eprints.gla.ac.uk/46340/ Deposited on: 22 November 2010 Enlighten – Research publications by members of the University of Glasgow http://eprints.gla.ac.uk Effects of ethylenediamine – a putative GABA-releasing agent – on rat hippocampal slices and neocortical activity in vivo Trevor W Stone1 , Caleb Lui1 and Jonas I. Addae2 1 Neuroscience and Molecular Pharmacology, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, U.K. 2 Dept of Preclinical Sciences, St. Augustine Campus University of the West Indies, Trinidad and Tobago. Correspondence: Prof T. W. Stone, West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK. Tel - +44 141 330 4481; fax - +44 141 330 5481; e-mail - [email protected] 1 ABSTRACT The simple diamine diaminoethane (ethylenediamine, EDA) has been shown to activate GABA receptors in the central and peripheral nervous systems, partly by a direct action and partly by releasing endogenous GABA. These effects have been shown to be produced by the complexation of EDA with bicarbonate to form a carbamate. The present work has compared EDA, GABA and β-alanine responses in rat CA1 neurons using extracellular and intracellular recordings, as well as neocortical evoked potentials in vivo. Superfusion of GABA onto hippocampal slices produced depolarisation and a decrease of field epsps, both effects fading rapidly, but showing sensitivity to blockade by bicuculline.
    [Show full text]
  • Metabolic and Homeostatic Changes In
    University of Dundee Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species Kovac, Stjepana; Dinkova Kostova, Albena T; Herrmann, Alexander M; Melzer, Nico; Meuth, Sven G; Gorji, Ali Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18091935 Publication date: 2017 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Kovac, S., Dinkova Kostova, A. T., Herrmann, A. M., Melzer, N., Meuth, S. G., & Gorji, A. (2017). Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species. International Journal of Molecular Sciences, 18(9), 1-19. [1935]. https://doi.org/10.3390/ijms18091935 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 29. Sep. 2021 International Journal of Molecular Sciences Review Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy—Mitochondria, Calcium Dynamics and Reactive Oxygen Species Stjepana Kovac 1,*, Albena T.
    [Show full text]
  • Programa Cooperación Farma-Biotech 8º Encuentro (7 De Mayo De 2013)
    Programa Cooperación Farma-Biotech 8º encuentro (7 de mayo de 2013) Lorediplon: “best-in-class” product for insomnia treatment Madrid,,y 7 de mayo de 2013 Programa Cooperación Farma-Biotech 8º encuentro (7 de mayo de 2013) Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing the market d) Current status of development e) IPR protect io n f) Pitfalls & Risks to be considered 3. Partnering Opportunities Programa Cooperación Farma-Biotech 8º encuentro (7 de mayo de 2013) The Company Who we are IItnternati onal pri vat tlely-hhldheld pharmaceu tiltical company Founded in 1959 Mission Business areas To advance the wellbeinggy of society Pharmaceuticals OTCs & personal health Diagnostics Worldwide operations Fine chemicals Headquarter in Barcelona Food & feed additives Presence in 93 countries Programa Cooperación Farma-Biotech 8º encuentro (7 de mayo de 2013) The Company Total turnover 2012 €819 million (+2% vs 2011) International turnover €365 million (44% of total) Total staff 2012 2,201 (abroad 593) Inves tmen t in R&D 12. 1% ofitilf prescription sales Given the maximum rating by the Spanish national pharma assessment system (Profarma) Programa Cooperación Farma-Biotech 8º encuentro (7 de mayo de 2013) The Product - Target Indication Insomnia In 2010, there were 53 million prevalent cases of insomnia in the 7 MM (US, Japan, France, Germany, Italy, Spain, and UK). US (25.7 million), Japan (8.2 million), France (6.8 million), Germany and Italy (3.5 million), Spain and
    [Show full text]